Bastian Frehland

540 total citations
26 papers, 465 citations indexed

About

Bastian Frehland is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Organic Chemistry. According to data from OpenAlex, Bastian Frehland has authored 26 papers receiving a total of 465 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 17 papers in Cellular and Molecular Neuroscience and 6 papers in Organic Chemistry. Recurrent topics in Bastian Frehland's work include Pharmacological Receptor Mechanisms and Effects (22 papers), Neuroscience and Neuropharmacology Research (14 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (10 papers). Bastian Frehland is often cited by papers focused on Pharmacological Receptor Mechanisms and Effects (22 papers), Neuroscience and Neuropharmacology Research (14 papers) and Phenothiazines and Benzothiazines Synthesis and Activities (10 papers). Bastian Frehland collaborates with scholars based in Germany, Netherlands and United States. Bastian Frehland's co-authors include Bernhard Wünsch, Dirk Schepmann, Kirstin Lehmkuhl, Thomas Winckler, Julian A. Schreiber, Roland Fröhlich, Guiscard Seebohm, Kai‐Uwe Schmidtke, Dina Robaa and Wolfgang Sippl and has published in prestigious journals such as Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Bioorganic & Medicinal Chemistry.

In The Last Decade

Bastian Frehland

26 papers receiving 463 citations

Peers

Countries citing papers authored by Bastian Frehland

Since Specialization

Citations

This map shows the geographic impact of Bastian Frehland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bastian Frehland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bastian Frehland more than expected).

Fields of papers citing papers by Bastian Frehland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bastian Frehland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bastian Frehland. The network helps show where Bastian Frehland may publish in the future.

Co-authorship network of co-authors of Bastian Frehland

This figure shows the co-authorship network connecting the top 25 collaborators of Bastian Frehland. A scholar is included among the top collaborators of Bastian Frehland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bastian Frehland. Bastian Frehland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enantiomerically Pure Indazole Bioisosteres of Ifenprodil and Ro 25-6981 as Negative Allosteric Modulators of NMDA Receptors with the GluN2B Subunit 2024 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Julian A. Schreiber, Judith Schmidt, Bastian Frehland, Dirk Schepmann, Guiscard Seebohm, Bernhard Wünsch	1
2	Indazole as a Phenol Bioisostere: Structure–Affinity Relationships of GluN2B-Selective NMDA Receptor Antagonists 2023 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Nadine Ritter, (unknown), Julian A. Schreiber, Judith Schmidt, Bastian Frehland, Dirk Schepmann, Guiscard Seebohm, Bernhard Wünsch	8
3	Phenol‐benzoxazolone bioisosteres of GluN2B‐NMDA receptor antagonists: Unexpected rearrangement during reductive alkylation with phenylcyclohexanone 2022 ·Archiv der Pharmazie ·(unknown), Julian A. Schreiber, (unknown), Bastian Frehland, Dirk Schepmann, Constantin G. Daniliuc, Roland Fröhlich, Guiscard Seebohm, Bernhard Wünsch	3
4	Phenol—Benzoxazolone bioisosteres: Synthesis and biological evaluation of tricyclic GluN2B‐selective N‐methyl‐d‐aspartate receptor antagonists 2022 ·Archiv der Pharmazie ·(unknown), Julian A. Schreiber, (unknown), Bastian Frehland, Guiscard Seebohm, Dirk Schepmann, Bernhard Wünsch	3
5	Negative allosteric modulators of NMDA receptors with GluN2B subunit: Alanine‐derived benzoxazolone bioisosteres of 2‐methyl‐3‐benzazepine‐1,7‐diols 2022 ·Archiv der Pharmazie ·(unknown), Bastian Frehland, Dirk Schepmann, Bernhard Wünsch	3
6	Synthesis and pharmacological evaluation of enantiomerically pure endo-configured KOR agonists with 2-azabicyclo[3.2.1]octane scaffold 2021 ·Organic & Biomolecular Chemistry ·(unknown), (unknown), Bastian Frehland, Kirstin Lehmkuhl, Dirk Schepmann, Jens Köhler, Patrizia Diana, Bernhard Wünsch	5
7	A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors 2019 ·Communications Biology ·Julian A. Schreiber, Dirk Schepmann, Bastian Frehland, (unknown), (unknown), Thomas Budde, Michael Hollmann, Nathalie Strutz‐Seebohm, Bernhard Wünsch, Guiscard Seebohm	28
8	Optimization of the metabolic stability of a fluorinated cannabinoid receptor subtype 2 (CB2) ligand designed for PET studies 2018 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Henk de Vries, (unknown), (unknown), Bastian Frehland, Dirk Schepmann, Laura H. Heitman, Bernhard Wünsch	7
9	Optimization of pharmacokinetic properties by modification of a carbazole-based cannabinoid receptor subtype 2 (CB2) ligand 2017 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Henk de Vries, (unknown), (unknown), Bastian Frehland, Dirk Schepmann, Laura H. Heitman, Bernhard Wünsch	13
10	Deconstruction – reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors 2017 ·European Journal of Medicinal Chemistry ·(unknown), (unknown), Julian A. Schreiber, Dirk Schepmann, Bastian Frehland, Kirstin Lehmkuhl, Nathalie Strutz‐Seebohm, Guiscard Seebohm, Bernhard Wünsch	16
11	Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation 2017 ·European Journal of Medicinal Chemistry ·(unknown), Bastian Frehland, Dirk Schepmann, Dina Robaa, Wolfgang Sippl, Bernhard Wünsch	16
12	Novel GluN2B selective NMDA receptor antagonists: relative configuration of 7-methoxy-2-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ols 2016 ·Acta Crystallographica Section E Crystallographic Communications ·(unknown), Bastian Frehland, Roland Fröhlich, Bernhard Wünsch	1
13	Crystal structure of (1S,2R)-7-benzyloxy-2-methyl-3-tosyl-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol: elucidation of the relative configuration of potent allosteric GluN2B selective NMDA receptor antagonists 2016 ·Acta Crystallographica Section E Crystallographic Communications ·(unknown), Bastian Frehland, Roland Fröhlich, Bernhard Wünsch	1
14	Stereoselective synthesis and pharmacological evaluation of [4.3.3]propellan-8-amines as analogs of adamantanamines 2015 ·Bioorganic & Medicinal Chemistry ·Héctor Torres‐Gómez, Kirstin Lehmkuhl, Bastian Frehland, Constantin G. Daniliuc, Dirk Schepmann, Christina Ehrhardt, Bernhard Wünsch	6
15	Synthesis, σ Receptor Affinity, and Pharmacological Evaluation of 5‐Phenylsulfanyl‐ and 5‐Benzyl‐Substituted Tetrahydro‐2‐benzazepines 2014 ·ChemMedChem ·(unknown), Bastian Frehland, Dirk Schepmann, Bernhard Wünsch	6
16	Synthesis and pharmacological evaluation of like- and unlike-configured tetrahydro-2-benzazepines with the α-substituted benzyl moiety in the 5-position 2014 ·Organic & Biomolecular Chemistry ·(unknown), Bastian Frehland, Kirstin Lehmkuhl, Roland Fröhlich, Dirk Schepmann, Bernhard Wünsch	69
17	Characterization of Ligand Binding to the σ ₁ Receptor in a Human Tumor Cell Line (RPMI 8226) and Establishment of a Competitive Receptor Binding Assay 2011 ·Assay and Drug Development Technologies ·(unknown), Dirk Schepmann, Kirstin Lehmkuhl, Bastian Frehland, Bernhard Wünsch	13
18	Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols 2010 ·Bioorganic & Medicinal Chemistry ·(unknown), Bastian Frehland, Dirk Schepmann, (unknown), Thomas Winckler, Bernhard Wünsch	55
19	Design, Synthesis, and Biological Evaluation of 3‐Benzazepin‐1‐ols as NR2B‐Selective NMDA Receptor Antagonists 2010 ·ChemMedChem ·(unknown), Bastian Frehland, Dirk Schepmann, Kai‐Uwe Schmidtke, Thomas Winckler, Bernhard Wünsch	45
20	Development of a selective competitive receptor binding assay for the determination of the affinity to NR2B containing NMDA receptors 2010 ·Journal of Pharmaceutical and Biomedical Analysis ·Dirk Schepmann, Bastian Frehland, Kirstin Lehmkuhl, (unknown), Bernhard Wünsch	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact